By Fineline Cube 
US-based Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced that Sanofi (NASDAQ: SNY), a major French pharmaceutical company, has exercised its option to acquire exclusive global rights to Nurix’s STAT6 program, which includes the investigational candidate NX-3911. NX-3911 is an oral, highly selective STAT6 degrader designed to treat type 2 inflammation-related diseases by inhibiting STAT6 signaling.
Collaboration Background
This decision stems from a collaboration agreement signed in December 2019. Under the agreement, Sanofi utilized Nurix’s proprietary DEL-AI drug discovery platform to develop targeted protein degradation (TPD) therapies. The original deal included options for Sanofi to co-develop and co-promote up to two potential products. Sanofi made an upfront payment of USD 55 million and an additional USD 22 million to expand the collaboration scope. Previously, Sanofi exercised its first option for an undisclosed TPD asset in April this year.
Financial Details
With this latest move, Nurix will receive a USD 15 million license extension fee, bringing the total payments from Sanofi to USD 127 million to date. Nurix is also eligible for up to USD 465 million in additional milestone payments tied to the STAT6 program, along with potential sales royalties. The company retains an option for U.S. co-development and co-promotion rights.-Fineline Info & Tech